Supplied frozen diluted in RPMI 1640 with 20% heat inactivated fetal bovine serum (FBS), 10% glycerol and 2.5% dimethyl sulfoxide (DMSO)
Type 1 Interferon (Type I IFN)
After receipt, store the product at -70 ºC or below for retention of full activity. Thawed cells should be used within 30 minutes.
Type I IFN, Type 1 IFN, Type I Interferon, Type 1 Interferon, Human, IFN-alpha, IFN-beta, IFNa, IFNb, Interferon alpha, Interferon beta, iLite
Quantification of Interferon a or b using iLite Type 1 IFN Assay Ready Cells (click)
Measuring neutralizing antibodies to IFNa/b using iLite Type 1 IFN Assay Ready Cells (click)
Type 1 IFN Quantification (IU/ml): 7 - 17 hours incubation time
NAbs to IFN beta 1a (TRU/ml): 30 min + 18 hours
NAbs to IFN alpha: 30 min + 6 hours
*Please note that these applications are presented for suggested use only and have not been fully evaluated by PBL
The iLite Human Type I Interferon Responsive Cells are engineered cells optimized to express Firefly Luciferase under the control of an IFN a/b responsive promoter. IFNa or IFNb bind to the IFN a/b receptor on the cell surface and activate the IFN a/b regulated Firefly Luciferase reporter gene construct. Normalization of cell counts and serum matrix effects is obtained by a second reporter gene, a Renilla Luciferase reporter gene construct, under control of a constitutive promoter.
iLite Type I IFN Assay Ready Cells are growth arrested cells which are sensitive to human Type I Interferon. The cells can be used in a number of different assays for measuring the bioactivity of Type I Interferon or NAbs to IFN beta or NAbs to IFN alpha. The iLite IFN cells are the only commercially available cells capable of measuring either the bioactivity of type I interferon, NAbs to IFN beta or NAbs to IFN alpha.
Interferon alpha (IFNa) has been widely used to treat chronic viral hepatitis and a wide variety of malignant diseases, including hairy cell leukemia, basal cell carcinoma, chronic myeloid leukemia, and cutaneous T-cell lymphoma. Several different recombinant preparations of IFNa are available commercially; the most commonly used formulations include IFNa2a and IFNa2b. A number of studies have shown that development of anti-IFNa neutralizing antibodies (NAbs) is correlated with a loss of IFNa treatment efficacy.
Interferon beta (IFNb) is well established as first line therapy in relapsing/remitting multiple sclerosis. The occurrence of NAbs and binding antibodies (BAbs) to IFNb has been widely reported. Subjects with NAbs have shown reduced response to treatment with IFNb, having higher relapse rates, increased MRI activity and higher risk of disease progression. The frequencies and titers of NAbs vary depending on the preparation used, dose and frequency of administration and also the assay used to quantify them.
Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta. Hermanrud et al., 2016, J. Immunol Methods, 430:1-9
The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. Grossberg et al., 2001, J. Interferon Cytokine Res., 21:729-742
The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. Grossberg et al., 2001, J. Interferon Cytokine Res., 21:743-755
Sign up for our mailing list to be kept up-to-date on the latest promotions, company and product news.
About Our Products
PBL Assay Science offers scientists a comprehensive range of assay kits, interferons, cytokines, growth factors and antibodies. Our high quality products provide consistent, reliable performance and are suitable for use in a range of research applications.